ERBB2 and breast cancer: Since patients with T1N0 HER2+ and hormone-sensitive BC that receive endocrine therapy represent a low-risk group in which de-escalation of therapy may be considered, we performed a propensity-score matched analysis of OS based on receipt of radiation in this specific subgroup.